MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Exagen Gross Profit 2011-2026 | XGN
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Exagen
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 25.4 M | 21.6 M | 17.1 M | 12.7 M | - | 8.41 M | 4.78 M | 225 K | -1.05 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 25.4 M | -1.05 M | 11.1 M |
Quarterly Gross Profit Exagen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.1 M | 10.4 M | 9.12 M | - | 6.98 M | 9.06 M | 8.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.4 M | 6.98 M | 9.04 M |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
BioNano Genomics
BNGO
|
2.77 M | $ 1.16 | 3.12 % | $ 1.47 M |  USA |
 |
Brainsway Ltd.
BWAY
|
30.6 M | $ 24.37 | -0.16 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
364 M | $ 26.8 | -3.0 % | $ 297 M |  China |
 |
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M |  Britain |
 |
Danaher Corporation
DHR
|
14.5 B | $ 209.64 | 0.22 % | $ 149 B | USA |
 |
DarioHealth Corp.
DRIO
|
5.98 M | $ 11.26 | - | $ 319 M | Israel |
 |
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
2.63 M | - | - | $ 79.8 M | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 23.42 | 1.43 % | $ 708 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | China |
 |
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 209.3 | -0.11 % | $ 23.2 B | USA |
 |
Castle Biosciences
CSTL
|
53 M | $ 30.44 | 1.67 % | $ 846 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
81.6 M | $ 17.63 | -8.42 % | $ 948 M | USA |
 |
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
2.8 B | $ 72.79 | -0.41 % | $ 28.4 B | USA |
 |
Interpace Biosciences
IDXG
|
29.9 M | $ 1.74 | -5.95 % | $ 7.63 M | USA |
 |
Exact Sciences Corporation
EXAS
|
2.26 B | $ 103.39 | -0.06 % | $ 19.5 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4.01 B | $ 285.93 | -0.42 % | $ 23.8 B | USA |
 |
Guardant Health
GH
|
144 M | $ 95.36 | -0.04 % | $ 12 B | USA |
 |
QIAGEN N.V.
QGEN
|
967 M | - | - | $ 10.6 B |  Niderland |
 |
Charles River Laboratories International
CRL
|
958 M | $ 170.5 | 2.67 % | $ 8.45 B | USA |
 |
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | USA |
 |
Myriad Genetics
MYGN
|
577 M | $ 4.61 | 4.06 % | $ 427 M | USA |
 |
ICON Public Limited Company
ICLR
|
817 M | $ 103.45 | -0.61 % | $ 8.53 B |  Irlanda |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 3.5 | -9.32 % | $ 1.88 M | USA |
 |
IDEXX Laboratories
IDXX
|
2.66 B | $ 660.2 | 1.69 % | $ 53.1 B | USA |
 |
Illumina
ILMN
|
2.86 B | $ 123.23 | 0.26 % | $ 19.6 B | USA |
 |
Natera
NTRA
|
127 M | $ 209.8 | 0.13 % | $ 20.6 B | USA |
 |
IQVIA Holdings
IQV
|
3.79 B | $ 163.11 | -1.07 % | $ 28 B | USA |
 |
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
2.39 B | $ 1 375.3 | -0.28 % | $ 28.3 B |  Schweiz |
 |
Pacific Biosciences of California
PACB
|
52.8 M | $ 1.7 | 2.11 % | $ 431 M | USA |
|
Biodesix
BDSX
|
18.5 M | $ 13.3 | 2.15 % | $ 1.72 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
7.77 B | $ 31.48 | -0.06 % | $ 20 B | Niderland |
 |
Lantheus Holdings
LNTH
|
988 M | $ 74.86 | 1.7 % | $ 5.18 B | USA |
 |
Quidel Corporation
QDEL
|
1.35 B | $ 23.05 | 5.09 % | $ 971 M | USA |
 |
Biomerica
BMRA
|
498 K | $ 2.1 | - | $ 4.82 M | USA |